Biotron Limited
Biotron Limited Fundamental Analysis
Biotron Limited (BIT.AX) shows strong financial fundamentals with a PE ratio of -2.32, profit margin of 2230.61%, and ROE of -1.19%. The company generates $-0.0B in annual revenue with strong year-over-year growth of 10.24%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -66.5/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze BIT.AX's fundamental strength across five key dimensions:
Efficiency Score
WeakBIT.AX struggles to generate sufficient returns from assets.
Valuation Score
ExcellentBIT.AX trades at attractive valuation levels.
Growth Score
ExcellentBIT.AX delivers strong and consistent growth momentum.
Financial Health Score
ExcellentBIT.AX maintains a strong and stable balance sheet.
Profitability Score
WeakBIT.AX struggles to sustain strong margins.
Key Financial Metrics
Is BIT.AX Expensive or Cheap?
P/E Ratio
BIT.AX trades at -2.32 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, BIT.AX's PEG of 0.05 indicates potential undervaluation.
Price to Book
The market values Biotron Limited at 1.67 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -3.40 times EBITDA. This is generally considered low.
How Well Does BIT.AX Make Money?
Net Profit Margin
For every $100 in sales, Biotron Limited keeps $2230.61 as profit after all expenses.
Operating Margin
Core operations generate 2222.04 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-1.19 in profit for every $100 of shareholder equity.
ROA
Biotron Limited generates $-50.16 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Biotron Limited generates strong operating cash flow of $-2.11M, reflecting robust business health.
Free Cash Flow
Biotron Limited generates strong free cash flow of $-2.11M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $-0.00 in free cash annually.
FCF Yield
BIT.AX converts -39.03% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-2.32
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.05
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.67
vs 25 benchmark
P/S Ratio
Price to sales ratio
-5677.88
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.47
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-1.19
vs 25 benchmark
ROA
Return on assets percentage
-0.50
vs 25 benchmark
ROCE
Return on capital employed
-0.71
vs 25 benchmark
How BIT.AX Stacks Against Its Sector Peers
| Metric | BIT.AX Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -2.32 | 28.25 | Better (Cheaper) |
| ROE | -119.12% | 780.00% | Weak |
| Net Margin | 223061.06% | -20122.00% (disorted) | Strong |
| Debt/Equity | 0.00 | 0.30 | Strong (Low Leverage) |
| Current Ratio | 1.47 | 4.66 | Neutral |
| ROA | -50.16% | -14687.00% (disorted) | Weak |
BIT.AX outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Biotron Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
52.28%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
93.99%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
87.62%
Industry Style: Defensive, Growth, Innovation
High Growth